Nu Med Plus Stock Analysis
| NUMD Stock | USD 0.01 0.01 29.00% |
Nu Med Plus holds a debt-to-equity ratio of 0.037. Nu-Med Plus' financial risk is the risk to Nu-Med Plus stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Nu-Med Plus' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Nu-Med Plus' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Nu-Med OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Nu-Med Plus' stakeholders.
For many companies, including Nu-Med Plus, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Nu Med Plus, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Nu-Med Plus' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Nu-Med Plus' debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Nu-Med Plus is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Nu-Med Plus to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Nu-Med Plus is said to be less leveraged. If creditors hold a majority of Nu-Med Plus' assets, the OTC Stock is said to be highly leveraged.
Nu Med Plus is overvalued with Real Value of 0.0135 and Hype Value of 0.01. The main objective of Nu-Med Plus otc analysis is to determine its intrinsic value, which is an estimate of what Nu Med Plus is worth, separate from its market price. There are two main types of Nu-Med Plus' stock analysis: fundamental analysis and technical analysis.
The Nu-Med Plus otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Nu-Med Plus' ongoing operational relationships across important fundamental and technical indicators.
Nu-Med |
Nu-Med OTC Stock Analysis Notes
About 62.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.01. Nu Med Plus had not issued any dividends in recent years. Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.The quote for Nu Med Plus is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Nu Med Plus contact William Hayde at 801 746 3570 or learn more at https://www.nu-medplus.com.Nu Med Plus Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Nu-Med Plus' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Nu Med Plus or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Nu Med Plus generated a negative expected return over the last 90 days | |
| Nu Med Plus has high historical volatility and very poor performance | |
| Nu Med Plus has some characteristics of a very speculative penny stock | |
| Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu-Med Plus until it has trouble settling it off, either with new capital or with free cash flow. So, Nu-Med Plus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nu-Med to invest in growth at high rates of return. When we think about Nu-Med Plus' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (830.06 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nu Med Plus currently holds about 2.54 K in cash with (206.83 K) of positive cash flow from operations. | |
| Roughly 62.0% of Nu-Med Plus outstanding shares are owned by corporate insiders |
Nu-Med Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.14 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nu-Med Plus's market, we take the total number of its shares issued and multiply it by Nu-Med Plus's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 5th of February, Nu-Med Plus owns the Mean Deviation of 3.38, market risk adjusted performance of (2.07), and Information Ratio of (0.10). In relation to fundamental indicators, the technical analysis model lets you check practical technical drivers of Nu Med Plus, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We have collected data for twelve technical drivers for Nu-Med Plus, which can be compared to its peers in the sector. Please verify Nu Med Plus market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Nu Med Plus is priced correctly, providing market reflects its prevailing price of 0.0142 per share. As Nu Med Plus appears to be a penny stock we also strongly suggest to check its jensen alpha numbers.Nu Med Plus Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Moving Average is predictive technique used to analyze Nu Med Plus price data points by creating a series of averages of different subsets of Nu-Med Plus entire price series.
Nu-Med Plus Outstanding Bonds
Nu-Med Plus issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nu Med Plus uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nu-Med bonds can be classified according to their maturity, which is the date when Nu Med Plus has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| NSTAR ELEC 44 Corp BondUS67021CAJ62 | View | |
| ES 495 15 SEP 52 Corp BondUS67021CAT45 | View | |
| ES 455 01 JUN 52 Corp BondUS67021CAS61 | View | |
| ES 195 15 AUG 31 Corp BondUS67021CAR88 | View | |
| ES 31 01 JUN 51 Corp BondUS67021CAQ06 | View | |
| US67021CAP23 Corp BondUS67021CAP23 | View |
Nu-Med Plus Predictive Daily Indicators
Nu-Med Plus intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nu-Med Plus otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 0.71 | |||
| Day Median Price | 0.0142 | |||
| Day Typical Price | 0.0142 | |||
| Price Action Indicator | (0) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 29.85 |
Nu-Med Plus Forecast Models
Nu-Med Plus' time-series forecasting models are one of many Nu-Med Plus' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nu-Med Plus' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Nu Med Plus Debt to Cash Allocation
Many companies such as Nu-Med Plus, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu-Med Plus until it has trouble settling it off, either with new capital or with free cash flow. So, Nu-Med Plus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nu-Med to invest in growth at high rates of return. When we think about Nu-Med Plus' use of debt, we should always consider it together with cash and equity.Nu-Med Plus Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Nu-Med Plus' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Nu-Med Plus, which in turn will lower the firm's financial flexibility.Nu-Med Plus Corporate Bonds Issued
Most Nu-Med bonds can be classified according to their maturity, which is the date when Nu Med Plus has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Nu-Med OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Nu-Med Plus prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nu-Med shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Nu-Med Plus. By using and applying Nu-Med OTC Stock analysis, traders can create a robust methodology for identifying Nu-Med entry and exit points for their positions.
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Nu-Med Plus to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Complementary Tools for Nu-Med OTC Stock analysis
When running Nu-Med Plus' price analysis, check to measure Nu-Med Plus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu-Med Plus is operating at the current time. Most of Nu-Med Plus' value examination focuses on studying past and present price action to predict the probability of Nu-Med Plus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu-Med Plus' price. Additionally, you may evaluate how the addition of Nu-Med Plus to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |